Meeting
2024 ASCO Annual Meeting
Effect of p16 immunohistochemical expression (exp) on irinotecan in metastatic colorectal cancer (mCRC): A translational analysis of the TRIBE and TRIBE2 studies.
Authors
Marco Maria Germani
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
Marco Maria Germani , Roberto Moretto , Veronica Conca , Francesca Signorini , Agnese Proietti , Mirella Giordano , Daniele Rossini , Vittorio Studiale , Sabina Murgioni , Giacomo Di Paolo , Filippo Pietrantonio , Alessandra Russo , Ada Taravella , Alessandro Passardi , Alberto Zaniboni , Tiziana Pia Latiano , Alessandro Cappetta , Clara Ugolini , Chiara Cremolini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 3562)
DOI
10.1200/JCO.2024.42.16_suppl.3562
Abstract #
3562
Poster Bd #
225
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Real-world outcomes of patients with BRAF-mutated mCRC treated in the United States.
First Author: Matthew Braithwaite
Poster
2019 ASCO Annual Meeting
Impact of age on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.
First Author: Federica Marmorino
Poster
2019 ASCO Annual Meeting
Impact of gender on the safety profile of chemotherapy plus bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.
First Author: Gemma Zucchelli
